ArticleDiscover oncology2024

New findings on the incidence and management of CNS adverse reactions in ALK-positive NSCLC with lorlatinib treatment.

Fanfan Chu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.